Brokerages Set Tcr2 Therapeutics Inc (NASDAQ:TCRR) Target Price at $26.33

Shares of Tcr2 Therapeutics Inc (NASDAQ:TCRR) have received an average recommendation of “Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $26.33.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of equities research analysts have recently commented on TCRR shares. HC Wainwright started coverage on Tcr2 Therapeutics in a research report on Monday, November 4th. They set a “buy” rating and a $19.00 target price on the stock. Zacks Investment Research cut Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 10th. Finally, ValuEngine lowered shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 27th.

Shares of TCRR traded up $0.63 during midday trading on Tuesday, hitting $14.54. 35,100 shares of the company’s stock traded hands, compared to its average volume of 77,659. Tcr2 Therapeutics has a 1 year low of $10.04 and a 1 year high of $25.47. The stock has a market capitalization of $351.11 million and a price-to-earnings ratio of -0.15. The firm’s fifty day moving average is $14.93 and its 200-day moving average is $15.36.

Tcr2 Therapeutics (NASDAQ:TCRR) last posted its earnings results on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.11. As a group, research analysts expect that Tcr2 Therapeutics will post -4.99 EPS for the current fiscal year.

In related news, major shareholder Morana Jovan-Embiricos sold 64,104 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $17.11, for a total value of $1,096,819.44. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 484,313 shares of company stock worth $8,609,469 over the last ninety days. 39.07% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Tcr2 Therapeutics in the 2nd quarter worth approximately $1,511,000. Vanguard Group Inc. acquired a new stake in shares of Tcr2 Therapeutics during the 2nd quarter worth approximately $1,070,000. Parametric Portfolio Associates LLC increased its holdings in shares of Tcr2 Therapeutics by 23.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock worth $501,000 after buying an additional 6,672 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of Tcr2 Therapeutics during the 3rd quarter worth approximately $474,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Tcr2 Therapeutics during the 2nd quarter worth approximately $349,000. 33.26% of the stock is currently owned by hedge funds and other institutional investors.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Further Reading: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Leave a Reply

Your email address will not be published. Required fields are marked *

*